Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -220,096 | -140,834 | -453,810 | -327,246 | -237,565 |
| Depreciation Amortization | 9,371 | 4,955 | 18,209 | 13,109 | 8,837 |
| Accounts receivable | -6,064 | -2,701 | -7,878 | -10,961 | -4,862 |
| Accounts payable and accrued liabilities | 8,471 | -4,868 | 46,361 | 64,033 | 13,136 |
| Other Working Capital | -33,644 | -31,003 | -56,459 | -22,211 | -1,425 |
| Other Operating Activity | -29,603 | 27,681 | -40,544 | -63,809 | -15,268 |
| Operating Cash Flow | $-271,564 | $-146,770 | $-494,121 | $-347,085 | $-237,148 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 144,879 | 72,805 | 177,323 | 139,749 | 91,090 |
| PPE Investments | 2,119 | -27 | -28,671 | -22,920 | -9,804 |
| Purchase Of Investment | -95,459 | -29,526 | -279,478 | -115,244 | -104,278 |
| Investing Cash Flow | $51,539 | $43,252 | $-130,826 | $1,585 | $-22,992 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 535,592 | 566,098 | N/A | N/A | N/A |
| Common Stock Issued | 730 | 432 | 448,893 | 444,442 | 5,762 |
| Common Stock Repurchased | -112,065 | -118,004 | -25,561 | N/A | N/A |
| Other Financing Activity | -3,366 | -2,188 | -7,606 | -5,760 | -4,062 |
| Financing Cash Flow | $420,891 | $446,338 | $415,726 | $438,681 | $1,700 |
| Exchange Rate Effect | 39,770 | 4,362 | 45,657 | 34,672 | 17,487 |
| Beginning Cash Position | 474,917 | 500,801 | 691,542 | 689,263 | 704,285 |
| End Cash Position | 715,554 | 847,983 | 527,979 | 817,116 | 463,331 |
| Net Cash Flow | $240,637 | $347,182 | $-163,564 | $127,854 | $-240,954 |
| Free Cash Flow | |||||
| Operating Cash Flow | -271,564 | -146,770 | -494,121 | -347,085 | -237,148 |
| Capital Expenditure | -8,028 | -4,285 | -28,671 | -22,920 | -9,804 |
| Free Cash Flow | -279,592 | -151,055 | -522,792 | -370,005 | -246,953 |